

## *Saccharomyces boulardii* as effective probiotic against *Salmonella typhimurium* in Mice

Shahlaa M. Salih\*

Manhal F.Ahmed\*

Abeer Y.Abdul-Kareem\*\*



\*Al-Nahrain University - College of Science

\*\* University of Anbar - College of Medicine

### ARTICLE INFO

Received: 6 / 5 /2012

Accepted: 9 / 6 /2013

Available online: 03/11/2014

DOI: 10.37652/juaps.2013.104796

#### Keywords:

*Saccharomyces boulardii* ,  
probiotic,  
*Salmonella typhimurium*,  
Mice.

### ABSTRACT

This study was designed to investigate the protective role of *Saccharomyces boulardii* on intestinal section of mice infected with *Salmonella typhimurium*. Mice were divided into four groups. A control group is uninfected with bacteria represent (negative control) , a second group was infected with bacteria *S.typhimurium* 0.1 ml ( $2.5 \times 10^7$  cfu/ ml) only represent (positive control) , the third group Induced mice received oral dose of *S. boulardii* 0.1ml ( $1 \times 10^9$  cfu/mL). Treated mice received *S. boulardii* ( $1 \times 10^9$  cfu/mL) orally for 7 days, followed by *Salmonella* infection. At the end of the experimental period the histological Results showed that administration of *S. typhimurium* alone resulted in a necrosis, degenerative changes and inflammatory cells infiltration in intestinal sections as compared with normal section taken from uninfected mice, while pretreatment with the *S. boulardii* ameliorate this effect.

### Introduction:

In human, *Salmonella* spp. Are responsible for over one billion infections annually, with consequences ranging from self-limiting gastroenteritis to typhoid fever [1]. To initiate disease, *Salmonella* first adheres to and then induces its own uptake into intestinal epithelial cells through a specialized mechanism involving injection of virulence factors into host cells by a type III protein secretion system (TTSS) [2].

Gram-negative *Salmonella* sp. Is a common bacterial enteropathogen and is widely used in laboratory studies aimed toward understanding the basis of mucosal immune responses and diseases such as gastroenteritis and typhoid. Most laboratory studies are carried out using *S. Typhimurium* in mice, where disseminated infection with some similarities to human typhoid is observed. Typhoid fever affects more than 20 million individuals and causes more than 220,000 deaths annually [3,4].

In recent years, worldwide interest for the use of functional foods containing probiotic microorganisms for health promotion and disease prevention has increased significantly and according to

College of Science. E-mail address:

[dean\\_coll.science@uoanbar.edu.iq](mailto:dean_coll.science@uoanbar.edu.iq)

the Food and Agriculture Organization and the World Health Organization, a probiotic is “a live microorganism which, when administered in adequate amounts, confers a health benefit to the host”. [5] Lyophilized *Saccharomyces boulardii* is probiotic yeast used worldwide for the prevention and treatment of a variety of diarrheal diseases [6]. In the case of infectious diarrhea, administration of *S. boulardii* to animals provides protection against intestinal lesions caused by several diarrheal pathogens [7].

Indeed, controlled clinical trials have shown that oral administration of *S. boulardii* could treat or prevent gastrointestinal diseases such as antibiotic-associated diarrhea [8], recurrent *Clostridium difficile*-associated diseases [9], traveller• diarrhea [10] , children acute diarrhea [11], bowel disease such as Crohn's• disease and ulcerative colitis [ 12,13] and irritable bowel syndrome [14]. This study was carried out to evaluate the treatment role of *Saccharomyces boulardii* on mice infected with *Salmonella typhimurium*.

\* Corresponding author at: Al-Nahrain University -

## Materials and Methods:

### Microbial isolates:

*S.typhimurium* was supplied by Central Public Health Lab. Which was previously isolated from stool sample of infant suffer from diarrhea, *S. boulardii* was bought as commercial lyophilized yeast (Ultra-Levure®, BIOCODEX, France).

### Bacterial culture:

*S.typhimurium* strain was grown overnight at 37°C in brain heart infusion broth. This activated culture was centrifuged at 3,000 rpm for 5 min, washed with sterile phosphate-buffered saline (PBS, pH 7.4), and resuspended in PBS to a final concentration of  $2.5 \times 10^7$  bacteria/ml [15].

Determination of the *S. typhimurium* susceptibility to antibiotics.

Disk diffusion test was used for testing susceptibilities of isolates to different antibiotics. Ten ml of nutrient broth medium were inoculated with bacterial isolates, the cultures were incubated at 37°C to mid log phase (18hrs). 100µl of inoculated broth then transferred to Muller-Hinton agar plates. A sterile cotton swab was used in three different planes to obtain an even distribution for inoculating triplicate plates [16].

With sterile forceps, the selected antibiotic disks were placed on the inoculated plate. All plates were incubated at 37°C for 24 hrs in an inverted position. Then diameter of inhibition zone was noted and measure by a ruler in mm.

### Experimental design:

Twenty adults albino male mice were randomly divided into four groups designated as 1, 2, 3, and 4. Each group consists of 5 mice, and subjected to the following treatments according to [17].

Group1: This group was used as a negative control.

Group2: This group was dosed with 0.1ml. of  $2.5 \times 10^7$ cfu/ml *S.typhimurium* culture and considered as positive control.

Group3: This group was dosed with 0.1ml of  $1 \times 10^9$ cfu/ml *S. boulardii* culture.

Group4: This group was dosed with 0.1ml of  $1 \times 10^9$ cfu/ml *S. boulardii* culture, and infected with 0.1ml of  $2.5 \times 10^7$  cfu/ml culture of *S.typhimurium*.

Mice were dosed with a single dose( 0.1 ml) of  $1 \times 10^9$ cfu/ml *S. boulardii* culture daily by oral administration for 7 consecutive days. After 7 days treatment, at the 8th day of experiment period, each mouse was given 0.1 ml of  $2.5 \times 10^7$  *Salmonella* culture by oral administration. After 6th day of infection with *S.typhimurium*, mice were sacrificed by cervical dislocation and collected to evaluate histological effect. Pieces were taken from intestine and put in petridishes containing physiological salty solution to remove the fatty tissues and sticky bundles, then the organ was kept in test tubes containing 10 % formalin solution then wash, dehydrated, embedded in paraffin, sectioned at 4-5 micron thickness preparation [18]. The staining method was performed by using hematoxylin and eosin as a routine work for histological studies [19].

### Results and Discussion:

Susceptibility to different antibiotics as shown in table 1 revealed that *S. typhimurium* was sensitive to Carbencillin, Ciprofloxacin and Rifampicin and resistant to other antibiotics.

Results indicated that mice intestinal sections taken from the control group showed normal structure appearance of villi without any pathological changes as shown in figure 1A . While, in intestinal sections taken from mice infected with *S. typhimurium* showed shedding and necrosis of intestinal mucosa and villi inside the lumen of the intestine figure 1 B Mice fed with *S.boulardii* showed normal villi appearance, while mice infected with *S. typhimurium* and pretreated with *S.boulardii* revealed shortening of the intestinal villi with thinning of the intestinal mucosa and ameliorate cytotoxic effect of *Salmonella* as shown in figure 1 C and D. Susceptibility of *S.typhimurium* to different antibiotics exhibited their resistance to different antibiotics used in this study. These results were close to those of CDC [20] who found that *S. typhimurium* isolates resisted chloramphenicol, ampicillin, streptomycin, and tetracycline the drug resistance genes can be transferred among many species of enteric bacteria.

Results showed that intestinal section of mice infected with *Salmonella* resulted in widening and odema in the villi with slight exist of inflammatory cells. This might be attributed to its ability to destroy M cells found within Peyer's patches. It's known that *S. typhimurium* grows primarily inside the macrophages

of liver and spleen. It has been shown that within 30 min of infection, invasive *S. typhimurium* entered M cells found within the follicle-associated epithelium (FAE) of Peyer's patches. At 60 min, internalized bacteria were cytotoxic for the M cells and the dead cell formed a gap in the FAE, which allowed bacteria to invade adjacent enterocytes or rapidly migrate to a number of sites in the body, including the spleen and liver, where they replicated inside phagocytic cells[21].

Results indicated that pretreatment with *S.boulardii* reduce the effect of *Salmonella* in intestinal pattern of mice. This protective effect could be due to immunomodulation or competition for nutrients or adhesion sites. The antagonism effect of *Sacchomyces* against *Salmonella* and *E.coli* mentioned by Gedek [22] who reported that the mannose in the cell wall may cause the yeast to act as a decoy for the attachment of pathogens the yeast acts as a pathogen adherent microflora (PAM) and binds organisms such as *Salmonella* that may enter the gastrointestinal tract before the bacteria can attach to the chicken's intestinal wall.

Rodrigues et al [23] reported that the immunomodulation effect of *S. boulardii* has been shown to increase intestinal secretory IgA production. sIgA is thought to inhibit the close association of pathogenic bacteria with the mucosal epithelium, and so to reduce bacterial penetration and more efficient clearance of *S. bouladii* against *E.coli* B41 in mice was correlated with earlier production of IFN- $\gamma$  and IL-12 which are involved in the T-helper 1 response.

Another study proved that *S. boulardii* interferes with the host cell signalling pathways and decreases the expression of inflammation-associated cytokines such as interleukin 8 (IL-8), IL-6, IL-1 $\beta$ , tumor necrosis factor alpha (TNF- $\alpha$ ) and interferon gamma (IFN- $\gamma$ ) [24], [25] and [26].

**Table 1: Susceptibility of *Salmonella typhimurium* to antibiotics.**

Antibiotic (Symbol)	Susceptibility
Amikacin(AK), Amoxicillin(Ax), Ampicillin(Am), Ceftazidime ( CAZ), Cephalxin (CL), Co- trimoxazole(SXT), Chloramphenicol(C) Gentamycin(CN), Kanamycin(K), Neomycin (N), Tetracycline(T), Tobramycin (Tob)	R
Carbencillin(Py),	S

Ciprofloxacin(Cip), Rifampicin (Rif)	
Ceftriaxone	Int

R: resistant, S: sensitive, Int: intermediate.




Figure 1: A Section of intestine of normal mice showing normal structure appearance of intestinal villi B Section in small intestine in mice infected with *S.typhimurium* showing infiltration in the lamina propria in the middle of the villi with odema C Section in small intestine in mice treated with *S. boulardii* showing normal villi appearance D

Section in small intestine of mice treated with *S. boulardii* and infected with *S.typhimurium* showing the shortening of the intestinal villi with thinning of the intestinal mucosa (arrows) (HE) ×100.

#### References:

- 1- Galán JE, Bliska JB (1996) Cross-talk between bacterial pathogens and their host cells. *Annu Rev Cell Dev Biol* 12: 221–255.  
Find this article online 2- Galán JE, Collmer A (1999) Type III secretion machines: bacterial devices for protein delivery into host cells. *Science* 284: 1322–1328.
- 3-Crump, J.A.,Luby, S.P.,and Mintz, E.D.(2004).The global of typhoid fever. *Bull.Worled Health Organ.*82.346-353.
- 4-Woc-Colbum,L.,and Bobak,D.A. (2009).The expanding spectrum of diseases due to salmonella:an international perspective.*Curr.Infect.Dis.Rep.*11,120-124
- 5- FAO/WHO (2002) Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada.
- 6- Czerucka D, Piche T, Rampal P (2007) Review article: yeast as probiotics-*Saccharomyces boulardii*. *Aliment Pharmacol Ther* 26: 767–778.
- 7- Find this article online 7- Czerucka D, Rampal P (2002) Experimental effects of *Saccharomyces boulardii* on diarrheal pathogens. *Microbes Infect* 4: 733–739.
- 8- Kotowska, M., Albrecht, P., and Szajewska, H. (2005). *Saccharomyces boulardii* in the prevention of antibiotic- associated diarrhoea in children: a randomized double- blind placebo-controlled trial. *Aliment Pharmacol Ther* 21, 583-590.
- 9- McFarland, L. V. (2006). Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of *Clostridium difficile* disease. *Am J Gastroenterol* 101, 812-822.
- 10- McFarland, L. V. (2007). Meta-analysis of probiotics for the prevention of traveler• fs diarrhea. *Travel Med Infect Dis* 5: 97-105. ,
- 11- Htwe, K., Yee, K. S., Tin, M., and Vandenplas, Y. (2008). Effect of *Saccharomyces boulardii* in the Treatment of Acute Watery Diarrhea in Myanmar Children: A Randomized Controlled Study. *Am J Trop Med Hyg* 78, 214-216.
- 12- Guslandi, M., Giollo, P., and Testoni, P. A. (2003). A pilot trial of *Saccharomyces boulardii* in ulcerative colitis. *Eur J Gastroenterol Hepatol* 15, 697-698
- 13- Guslandi, M., Mezzi, G., Sorghi, M., and Testoni, P. A. (2000). *Saccharomyces boulardii* in maintenance treatment of Crohn’s disease. *Dig Dis Sci* 45, 1462-1464.
- 14- Maupas, J., Champemont, P., and Delforge, M. (1983). Treatment of irritable bowel syndrome with *Saccharomyces boulardii*: a double-blind, placebo-controlled-study. *Med Chir Dig* 12, 77-79.
- 15- Lilian, N.M. ; Elizabeth N.; and Jacques R. Nicoli, Protection by *Lactobacillus acidophilus* ufv-h2b20 against experimental oral infection with *Salmonella typhimurium* in gnotobiotic and conventional mice.*brazilian journal of microbiology* (2001).
- 16- Atlas, R. M.; Brown, A. E. and Parks L. L. (1995). *Laboratory Manual of Experimental Microbiology* (1st Ed.). Mosby. Inc. Missouri.
- 17- Mahzounieh, M. ; Karimi, T., and Marjianian, R., (2006).The preventive of *Saccharomyces boulardii* in pathogenesis of *Salmonella typhimurium* in experimentally infected rats. *Pak. J. of Bio.Sci.*, 9(4): 632-635
- 18- Lin WH, Yu B, Lin CK, Hwang WZ, Tsen HY. (2007). Immune effect of heat-killed multistrain of *Lactobacillus acidophilus* against *Salmonella typhimurium* invasion to mice. *Appl Microbiol.*; 102 (1):22-31
- 19- Bankroft, L. (1980). *Basic histological techniques*; 4th ed; an Arboer science publishers. Pp: 130-145.
- 20- CDC.(2009) National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2006. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC,
- 21- Jones, B. D. & Falkow, S. (1996). Salmonellosis: host immune responses and bacterial virulence determinants. *Annu Rev Immunol* 14, 533–561.
- 22- Gedek, B. (1999) Adherence of *E.coli* serogroup O 157 and the *Salmonella typhimurium* mutant DT 104 to the surface of *S.boulardii*. *Mycoses* 42(4): 261-64
- 23- Rodrigues, A. C., Cara, D. C., Fretez, S. H. G. G., Cunha, F. Q., Vieira, E. C., Nicoli, J. R. & Vieira, L. Q. (2000). *Saccharomyces boulardii* stimulates sIgA production and the phagocytic system of gnotobiotic mice. *J Appl Microbiol* 89, 404–414.
- 24- Dahan, S., Dalmasso, G., Imbert, V., Peyron, J. F., Rampal, P., and Czerucka, D. (2003).

Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli- induced signaling pathways in T84 cells. Infect Immun 71, 766-773

25- Dalmaso, G., Loubat, A., Dahan, S., Calle, G., Rampal, P., and Czerucka, D. (2006b). Saccharomyces boulardii prevents TNF-alpha-

induced apoptosis in EHEC-infected T84 cells. Res Microbiol 157, 456-465.

26- Mummy, K. L., Chen, X., Kelly, C. P., and McCormick, B. A. (2007). Saccharomyces boulardii interferes with Shigella pathogenesis by post-invasion signaling events. Am J Physiol Gastrointest Liver Physiol 294, G599-609.

## الدور العلاجي لخميرة *Sacchromyces boulardii* في الفئران المصابة ببكتريا *Salmonella typhimurium*

شهلاء مهدي صالح      منهل فاروق احمد      عبير يوسف عبد الكريم

E.mail: [dean\\_coll.science@uoanbar.edu.iq](mailto:dean_coll.science@uoanbar.edu.iq)

الخلاصة :

اجريت هذه الدراسة لتقييم الدور الوقائي لخميرة *Sacchromyces boulardii* في امعاء الفئران المصابة ببكتريا ال *S.typhimurium* , درس التأثير على 20 فارة بيضاء والتي قسمت الى اربعة مجاميع ,مجموعة سيطرة غير مصابة بالبكتريا تمثل (negative control) ومجموعة ثانية تم إصابتها ببكتريا ال *S.typhimurium* 0.1ml ( $2.5 \times 10^7$  cfu/ml) فقط تمثل (positive control) اما المجموعة الثالثة جرعت بخميرة *S. boulardii* 0.1ml ( $1 \times 10^9$  cfu/mL) هي المجموعة المعاملة جرعت بخميرة *S.typhimurium* 0.1ml ( $1 \times 10^9$  cfu/mL) فقط, والمجموعة الرابعة هي المجموعة المعاملة جرعت بخميرة *S.typhimurium* 0.1ml ( $2.5 \times 10^7$  cfu/ml) . اظهرت نتائج الدراسة النسيجية ان اصابة الفئران ببكتريا *S.typhimurium* تسبب بتغيرات وتحولات انحلالية وارتشاح الخلايا الالتهابية في امعاء الفئران مقارنة بالمقاطع الطبيعية المأخوذة من الفئران الغير مصابة. كما اظهرت النتائج ان معالجة الفئران بالخميرة ادى الى خفض التأثير المرضي لبكتريا *S.typhimurium* في الفئران المصابة.